JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Elenco Azioni・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Chiusa

SettoreSettore sanitario

1.2

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.2

Massimo

1.21

Metriche Chiave
By Trading Economics
Entrata	8.8M -51M
Margine di Profitto	272,450
Dipendenti	226
EBITDA	-335K -57M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+683.33% upside

Dividendi
By Dow Jones
Utili prossimi	6 nov 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	61M 286M
Apertura precedente	1.2
Chiusura precedente	1.2

Notizie sul Sentiment di mercato

By Acuity

56%

44%

301 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

1.18 / 1.69 Supporto e resistenza

Allogene Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ott 2025, 18:41 UTC

Utili

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 ott 2025, 18:31 UTC

Utili

Correction to Procter & Gamble to Focus on Innovation

24 ott 2025, 16:25 UTC

I principali Market Mover

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 ott 2025, 21:07 UTC

Utili

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 ott 2025, 20:58 UTC

Utili

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 ott 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 20:40 UTC

Utili

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 ott 2025, 20:24 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:23 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:13 UTC

Utili

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 20:07 UTC

Discorsi di Mercato

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 ott 2025, 19:40 UTC

Discorsi di Mercato

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 ott 2025, 19:35 UTC

Discorsi di Mercato

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 ott 2025, 19:33 UTC

Utili

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 ott 2025, 19:29 UTC

Discorsi di Mercato

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 ott 2025, 18:52 UTC

Utili

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:41 UTC

Utili

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:03 UTC

Utili

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 ott 2025, 18:02 UTC

Utili

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 ott 2025, 18:00 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 ott 2025, 16:57 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 ott 2025, 16:54 UTC

Discorsi di Mercato

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 ott 2025, 16:44 UTC

Discorsi di Mercato

Utili

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 ott 2025, 16:39 UTC

Discorsi di Mercato

Utili

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 ott 2025, 16:33 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:23 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 16:07 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Allogene Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

683.33% in crescita

Previsioni per 12 mesi

Media 9.4 USD 683.33%

Alto 14 USD

Basso 7 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Allogene Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Allogene Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.18 / 1.69Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

301 / 371 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.